Skip to main content
main-content

01.12.2017 | Research article | Ausgabe 1/2017 Open Access

BMC Cancer 1/2017

MEIS1 inhibits clear cell renal cell carcinoma cells proliferation and in vitro invasion or migration

Zeitschrift:
BMC Cancer > Ausgabe 1/2017
Autoren:
Jie Zhu, Liang Cui, Axiang Xu, Xiaotao Yin, Fanglong Li, Jiangping Gao
Abbreviations
AML
Acute myeloid leukemia
ccRCC
Clear cell renal cell carcinoma
CDK
Cyclin dependent kinase
ECM
Extracellular matrix
EMT
Epithelial-mesenchymal transition
MEIS1
Myeloid ecotropic viral integration site 1
NSCLC
Non-small-cell lung cancer
PI
Propidium iodide
PVDF
Poly-vinylidene fluoride
TALE
Triple amino acid loop extension

Background

As a member of TALE (Triple amino acid loop extension) transcription factors, MEIS1 contains a homeodomain which is generally recognized be important for its roles in cell growth and differentiation during vertebrate embryogenesis [ 13]. MEIS1 also plays a critical role in development and stem cells regulation [ 46]. Various genetic alterations occur in AML that lead to overexpression of the MEIS/HOXA9 complex, which plays a synergistic causative role in acute myeloid leukemia (AML) development [ 710]. However, a range of recent work also revealed that MEIS1 would also be found as a negative regulator in some other cancers, e.g. non-small-cell lung cancer or prostate cancer [ 1113]. In these cancers, MEIS1 would function via inhibiting cell proliferation and inducing cell cycle arrest [ 1113]. High level of MEIS1 was detected in normal prostate compared with prostate tumor tissues; indicating that it would be a useful biomarker or even a therapeutic target of human prostate carcinoma [ 13]. Rad et al reported that MEIS1 level is inversely correlated with tumor metastasis and tumor staging of esophageal squamous cell carcinoma [ 14]. Xu et al showed that MEIS1 would interact with Hox (homeobox protein family) and Pbx1 (pre-B-cell leukemia homeobox 1) [ 15]. Our previous work also indicated that MEIS1 is a negative regulator of androgen receptor (AR) pathway [ 16]. To unmask thorough roles by which MEIS1 affect cancer physiology, more studies should be done.
The ccRCC is one of the most common malignancies, and it is the second leading cause of death among patients suffering from urologic tumors [ 17, 18]. Nowadays, partial nephrectomy is the most effective treatment for local ccRCC [ 18]. As to chemotherapy and radiotherapy, the prognosis of advanced metastatic ccRCCs still remains very poor because tumor tissue has low sensitivity to those therapeutic agents [ 1720]. Although certain kinase inhibitors have been used in clinical application, such as sorafenib and sunitinib, several problems have been raised during recent trials, i.e. the risk of adverse events and un-anticipated efficacy-loss, which may due to the off target effects of current agents [ 19, 20]. Therefore, it is of great importance to identify novel molecular targets for ccRCC treatment.
In this study, we find that MEIS1 is less expressed in some ccRCC cell lines and ccRCC specimens than in non-tumor kidney cells and specimens. Overexpression of MEIS1 significantly inhibits cell survival and induces cell cycle G1/S phase arrest of ccRCC cells 786-O and Caki-1. Furthermore, we demonstrate that reestablishment of MEIS1 expression in high aggressive ccRCC cell line Caki-1 leads to dramatic in vitro cell invasion and migration reduction and decreased EMT process. Moreover, overexpression of MEIS1 also inhibits in vivo growth of Caki-1 cells in mouse model.

Methods

Plasmids and adenovirus vector preparation

The MEIS1 expression vector or its small interfering RNA (siRNA) was as previously described [ 16]. Adenovirus vectors of MEIS1 were generated following the methods as described by Niu et al. [ 21]. Briefly, full length cDNA of Meis1 gene was cloned into pShuttle-CMV vector. Then, pAdEasy-1 vector and pShuttle- Meis1 vector was co-transformed into BJ5183 cells to produce the recombinant adenovirus vector pAd-control or pAd-MEIS1. For packaging step, pAd-control or pAd-MEIS1 was transfected into AD-293 cells and then purified with a cesium chloride gradient. All vectors were confirmed by Sanger sequencing.

Cell culture and reagents

Human ccRCC cell lines 786-O or Caki-1 (a high metastatic cell line), and non-tumor cell lines HEK293 (a human embryonic kidney cell line) or HKC (a human kidney non-tumor cell line) were as previously described [ 18]. 786-O, Caki-1 and HKC cells were cultured in complete DMEM (Invitrogen, Carlsbad, CA, USA), and HEK293 was cultured in RPMI-1640 medium (Invitrogen, Carlsbad, CA, USA) in a sterile incubator maintained at 37 °C with 5% CO 2.

Cell growth and colony formation assays

For measuring proliferation, Caki-1 or 786-O cells, which were infected with Ad-control or Ad-MEIS1, were seeded in 96-well plates (Corning, NY, USA), incubated for 1, 2, 3 and 4 days, and the cells were analyzed for MTT assays [ 22]. HKC cells were transfected with siRNA of MEIS1 and then harvested for MTT analysis.
For colony formation, infected ccRCC cells were seeded in 6-well plates at 500 cells per well [ 23]. Two to four weeks later, colonies were fixed with 4% paraformaldehyde and stained with 0.5% (W/W) crystal violet (diluted in phosphate buffer saline, PBS) for 30 min. Next, cells were harvested and measured by a multifunctional micro-plate reader at 546 nm. The relative colony number (relative survival cell number) =  O.D. 546 administration group / O.D. 546 control group. HKC cells, which were transfected with siRNA of MEIS1, were also measured by colony formation assays.

Cell cycle analysis

Cell cycle was carried out by flow-cytometry following the instructions as previously described by Chen et al [ 24]. ccRCC cells, which were infected with Ad-control or Ad-MEIS1, were fixed in 70% ethanol for 18-24 h. Next, cells were washed with pre-cold PBS for three times and incubated with RNase A (0.2 mg/mL) diluted in pre-cold PBS. Then, PI (propidium Iodide) was added. Samples were analyzed by FACScalibur Flow Cytometer (Becton Dickinson, Bioscience, USA).

Cell death analysis

Caki-1 or 786-O cells, which were infected with Ad-control or Ad-MEIS1, were harvested and labelled with PI and FITC-Annexin V according to the manufacturer’s instructions (Becton Dickinson, Biosciences, USA). A minimum of 2000 events for each sample were collected and analyzed using a FACScalibur Flow Cytometer (Becton Dickinson, Biosciences, USA).

Real-time PCR (qPCR)

Total RNA samples of cells or clinical specimens were obtained by previously [ 18, 25]. The qPCR was performed according to the manufacturer’s instructions (Applied Biosystems, Foster City, CA, USA) using total RNA sample as templates. The primers used to amplify MEIS1 expression are: forward: 5’-TCCCAA AGTAGCCACCAATATC-3’; and reverse: 5’-CTGTATCTGTGCCAAC TGCTT-3’

Anchorage-independent growth

Caki-1 or 786-O cells, which were infected with Ad-control or Ad-MEIS1, were plated into 6-well plates (1000 cells per well) (Corning, Corning, NY, USA), with a bottom layer of 1.0% low melting temperature agar in DMEM and a top layer of 0.3% agar in DMEM. Colony number was manifested as the mean ± SD of three independent experiments scored after 3-4 weeks of growth [ 26].

Transwell migration assays (in vitro invasion or migration)

Caki-1 cells, which were infected with Ad-control or Ad-MEIS1, were analyzed by transwell migration assays performed in 24-well plates chamber (Corning, NY, USA) by fitted with a polyethylene terephthalate filter membrane with 8 μm pores. For invasion, the top chambers was coated with 30 μl ECM (Extracellular matrix) gel (Sigma, USA) diluted with serum free RPMI-1640 in 1:5 dilution for more than 4 h at 37 °C. Then, chambers were filled with 0.2 ml of cells (5 × 10 5 cells per ml) in serum-free medium, and the bottom chambers were filled with 0.25 ml of medium with 10% FBS. The cells were incubated in the trans-wells at 37 °C in 5% CO 2 for 12 h. For migration, the cells were incubated in chambers without ECM coated. After 10-15 h (for invasion) or 4-6 h (for migration), chamber membrane was fixed with 4% paraformaldehyde and stained with crystal violet. The relative invading cells were measured according to the instructions provided [ 27, 28]. Values were presented as the mean ± SD of triplicated experiments.

Antibodies and western blot

Antibodies against MEIS1, Cyclin D1, Cycline A, cIAP1/2, Survivin, E-cadherin, N-cadherin, Vimentin, BAX and GAPDH were obtained from Santa Cruz Biotechnology (Santa Cruz Biotech, CA, USA). Polyclonal IgG conjugated with horseradish peroxidase (HRP) was obtained from Sigma (St. Louis, MO, USA). Total protein samples were performed by SDS-PAGE and trans-printed to poly-vinylidene fluoride (PVDF) membranes (Millipore, Billerica, MA). Then, membranes were blocked with 5% BSA in TBST buffer and then incubated 2 h at 37 °C with primary antibody against MEIS1 (1:1000), Cyclin D1 (1:500), Cyclin A (1:500), cIAP-1 (1:1000), cIAP-2 (1:1000), Survivin (1:2000), E-cadherin (1:1000), N-cadherin (1:1000), Vimentin (1:2000), BAX (1:500) and GAPDH (1:5000) diluted in TBST containing 5% BSA and subsequently washed three times in TBST for 5 min each. Then membranes were incubated with the HRP-conjugated secondary antibodies (1:5000) after being washed three times in TBST for 5 min each. At last, blots were developed with enhanced chemiluminescence reagents by X-ray films. The blots were performed on three experiments with similar results.

In vivo analysis

In vivo nude mice model was created via xenotransplantation of Caki-1 cells into 4-5 week-old nude mice (6 animals per group) [ 29]. Caki-1 cells, which were infected with Ad-control or AD-MEIS1, were injected with 5 × 10 5 cells re-suspended in PBS or normal/physiological saline. Tumor volumes were measured every week by measuring length and width. Volumes of tumor were calculated: (width 2 × length) / 2 [ 29]. Animal Experiment Committee of General Hospital of Chinese PLA approved all protocols for treating animals, and the in vivo studies were carried out in accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and associated guidelines.

Statistical analysis

The WB results were analyzed by the ALPHA INNOTECH analysis software. The relative expression level was calculated: (indicated group protein expression level/loading control expression level)/(control group protein expression level/loading control expression level). All statistical significance analyses were performed using SPSS statistical software. P-value of <0.05 was considered statistically significant. Statistical significance in cell growth assays was analyzed by Bonferroni correction with or without two-way ANOVA.

Results

MEIS1 is expressed in ccRCC cell lines and tissues

First, the endogenous level of MEIS1 in ccRCC and non-tumor kidney cells was examined by WB. As shown in Fig.  1a, b, high level of MEIS1 was detected in non-tumor cell line, HEK-293 and HKC. In contrast, MEIS1 expression in ccRCC cell lines Caki-1 and 786-O was much lower. Next, the expression of MEIS1 in ccRCC clinical specimens was detected (Fig.  1c). Ten paired ccRCC/non-tumor cDNA samples were analyzed by qPCR. The endogenous level of MEIS1 was significantly lower in ccRCC samples than in adjacent non-neoplastic clinical specimens (Fig.  1c). Our data from cell lines and clinical specimens suggest that loss of MEIS1 may play a role in the progression of ccRCC.
Next, to further study the detailed functions of MEIS1 in ccRCC, we generated MEIS1 expressing adenoviral vectors. Ad-control carries out the empty vector and Ad-MEIS1 contains full length coding sequence of Meis1 gene. Caki-1 or 786-O cells were infected with Ad-control or Ad-MEIS1. The protein level of MEIS1 was significantly increased upon Ad-MEIS1 infection (Fig.  1d, e).

MEIS1 suppresses ccRCC cells proliferation

To test whether MEIS1suppresses ccRCC proliferation, we performed MTT assay. Caki-1 and 786-O cells that were infected with Ad-MEIS1 grew slower than those infected with Ad-controls or their parental cells (Fig.  2a, b). Since there was no significant difference between the parental cells and cells infected with Ad-controls (Fig.  2a, b), our data suggest that MEIS1 overexpression inhibits ccRCC cell growth. Moreover, colony formation assay (CFAs) showed that colony number was reduced in MEIS1 overexpressing Caki-1 or 786-O cells than in control cells (Fig.  2c-f). Together, these results reveal that MEIS1 may attenuate the proliferation and colony formation of ccRCC cells.
Next, to confirm MEIS1’s function, we knockdown MEIS1 in HKC cells; HKC is a normal human kidney cell line highly expressing endogenous MEIS1. As shown in Fig.  3, knockdown of MEIS1 via its siRNA enhanced the proliferation (Fig.  3a-c), colony number and size (Fig.  3d-f) of HKC cells. These results confirmed that MEIS1 negatively regulates cell growth and proliferation.

MEIS1 decreases the anchorage-independent growth of ccRCC cells

To further examine tumor-suppressing activity of MEIS1, soft-agar assay was performed to examine the anchorage-independent growth of ccRCC cells. Our results indicated that MEIS1 overexpression inhibited anchorage-independent growth of Caki-1 and 786-O cells (Fig.  4a,b).

MEIS1 overexpression induces non-apoptotic death of ccRCC cells

Next, we examined whether MEIS1 participates in regulating cell death of ccRCC. As shown in Fig.  5, the proportion of non-apoptotic death increased after overexpressing MEIS1, from 3.12% to 19.58% (Caki-1), or 4.10% to 21.59 (786-O) (Fig.  5a, b).
To explain how MEIS1 regulates non-apoptotic cell death, we examined central components in this process. As shown in Fig.  6, overexpression of MEIS1 in Caki-1 cell reduced the expression of pro-survival proteins cIAP-1 (cellular inhibitor of apoptosis 1), cIAP-2 (cellular inhibitor of apoptosis 2) and Survivin (Fig.  6a). MEIS1 also increased the protein level of pro-apoptosis regulator BAX. Similar results were obtained from 786-O cells (Fig.  6b). These results demonstrate that the inhibitory activity of MEIS1 on ccRCC cells proliferation and survival may depend on its regulation on those pro-apoptosis related proteins.

MEIS1 overexpression induces ccRCC cell cycle arrest at G1/S transition

To further elucidate the mechanism by which MEIS1 negatively regulates ccRCC cells growth, we examined the effect of MEIS1 on cell cycle. Overexpression of MEIS1 in Caki-1 cells resulted in a reduction in proportion of cells in S phase (from 25.07% to 14.07%) and G2/M phase (from 14.85% to 3.25%) but an increase in proportion of cells in G0/G1 phase (from 58.25% to 75.68%) (Fig.  7a). Similar results were also obtained from 786-O cells (Fig  7b). MEIS1 overexpression increased the proportion of 786-O cells in G0/G1 phase (from 56.25% to 80.68%), and decreased S phase cells (from 26.07% to 12.07%) or G2/M cells (from 17.67% to 7.25%). These data indicated that MEIS1 could induce ccRCC cell cycle arrest at G1/S transitions.
To investigate how MEIS1 regulates cell cycle, we tested whether MEIS1 modulates the endogenous expression of positive G1/S transition regulators, Cyclin D1 and Cyclin A. As shown in Fig.  8, MEIS1 overexpression decreased Cyclin A and Cyclin D1 in ccRCC cells (Fig.  8a, b). Taken together, these data suggest that MEIS1 induces ccRCC cell cycle arrest at G1/S transitions via down-regulating cyclin A and cyclin D1.

MEIS1 overexpression inhibits in vitro invasion and migration of ccRCC cells with decreased EMT

Transwell migration assay (TMA) was used to assess the effect of MEIS1 on ccRCC cells in vitro invasion and migration. Our results indicated that overexpression of MEIS1 attenuates in vitro invasion (Fig.  9a) and migration (Fig.  9b) of the highly aggressive Caki-1 cells. Moreover, MEIS1 overexpression increased the expression of epithelial marker E-cadherin and decreased that of N-cadherin and Vimentin, two mesenchymal markers (Fig.  10a, b). These results, which were in consistent with TMA experiments, suggested that MEIS1 overexpression could inhibit the in vitro invasion and migration of Caki-1 cells via disrupting EMT process.

MEIS1 overexpression attenuates in vivo growth of Caki-1 cells in nude mice model

The effect of MEIS1 overexpression on in vivo growth of Caki-1 cells was examined in a xenograft nude mice model (Fig.  11). Infection of Ad-MEIS1 could significantly shrink the tumor volume or weight of Caki-1 compared with Ad-control. Thus, MEIS1 attenuates in vivo growth of Caki-1 cells in nude mice model.

Discussion

For the first time, our study discovers that MEIS1 may function as a tumor suppressor in ccRCC. First, MEIS1 expression is reduced in ccRCC tissues or cell lines; second, overexpression of MEIS1 suppresses proliferation, colony formation and anchorage independent growth of ccRCC cells; third, MEIS1 overexpression induces cell cycle G1/S arrest and non-apoptotic cell death of ccRCC cells. At molecular level, MEIS1 overexpression decreases the expression of pro-survival regulators cIAP-1, cIAP-2 and Survivin; whereas increases pro-apoptosis protein BAX. Further, MEIS1 overexpression can disrupt the metastasis of Caki-1 cells and leads to decreased EMT process. These findings expand our knowledge about MEIS1 and suggest that MEIS1 may play an important role in the development and progression of ccRCC and this work may carry out its potential application in ccRCC treatment.
Cell cycle checkpoints protect genomic integrity [ 30]. Alterations of cell cycle related proteins, including Cyclin or CDK, would be a hallmark for multiple of human cancers [ 31]. The transformation of human cancers usually accompanies with the deregulation of G1/S cell cycle checkpoint controls [ 32]. Cyclins and their associated CDKs are the central machinery that governs cell cycle progression [ 21]. Of the various cyclin/CDK complexes implicated in cell cycle progression, cyclin D1/CDK4/6 and cyclin D1/CDK4/6 and cyclin A/CDK1 are of great interest, because they mediate G1/S transition [ 3032]. In this study, we show that, in ccRCC, MEIS1 overexpression arrests cell cycle at G1/S transition, along with reduced expression of cyclin D1 and cyclin A. Previous reports showed that MEIS1 controls cells proliferation via regulating cyclinD1 and c-MYC level [ 3335]. These results indicated that MEIS1 could be an important cell cycle regulator and attenuate cell proliferation via disrupting cell cycle progression. CDK inhibitors, e.g. P15, P16, P21, P27 or Rb may inhibit the activity of cyclin/CDK complexes and be growth inhibitor [ 21]. Down-regulation of these inhibitors often associates with poor prognosis of human cancers, thus it is valuable to further study whether MEIS1 regulates expression of CDK inhibitors in the future.
Recent publications provided clues that MEIS1 may participate in tumor progression, including leukemogenesis, NSCLC or nephroblastoma progression [ 3638]. Among these works, MEIS1 is well-defined in modulating AML and prostate cancer progress. Also, MEIS1 would function as a tumor suppressor in some other kinds of human cancer [ 1114]. It promotes the differentiation and suppresses the proliferation of non-tumor prostate epithelial cells [ 3, 13]. Decreased expression of MEIS1 is predicted as worse overall survival (OS) while elevated level of MEIS1 was associated with improved OS in prostate cancer [ 3, 13]. Our previous work also indicated that MEIS1 functions as a negative AR regulator and inhibits the ligand-dependent growth of certain kinds of prostate cancer [ 16]. Based on the previous discovery of MEIS1, to further reveal its function and develop potential therapy in human cancer treatment are accessible. This work discovers, for the first time, MEIS1 as a tumor suppressor in ccRCC. In this work, MEIS1 overexpression could repress in vitro invasion and migration of high aggressive ccRCC cell line Caki-1 and lead to decreased EMT, the critical step mediating cancer metastasis. Since invasion and migration are main features of malignancies, our data reveal that MEIS1 overexpression could be a potential approach to improve the cancer prognosis of advanced metastatic ccRCC.

Conclusions

In summary, MEIS1 functions as a suppressor in ccRCC progression, supported by the fact that endogenous expression of MEIS1 reduces in ccRCC cells lines specimens Overexpression of MEIS1 significantly inhibits proliferation and apoptosis of ccRCC cells. These findings would help us to understand more about MEIS1 in cancerous cell proliferation and also provide a new potential approach to ccRCC treatment.

Acknowledgements

We thank Dr. B. Dai and Dr. Y. Cao for their advice and excellent technical assistances to this study.

Funding

This work was supported by direct grants from the Chinese Government: the National Natural Science Foundation of China (No. 81100483) and the National High Technology Research and Development Program of China (No. 2012AA021100). These funding sources or funding bodies had no role in the design of this study and will not have any role during its execution, analyses, interpretation of the data, or decision to submit the results.

Availability of data and materials

Additional data and materials may be requested from the corresponding author on reasonable request.

Authors’ contributions

JZ and LC performed the molecular genetic studies, sequence alignment and statistical analysis. AXX and FLL carried out the immunoassays. XTY performed the statistical analysis. JPG carried out the design of the study and drafted the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

The Animal Experiment Committee of Chinese PLA General Hospital approved all experiments or protocols for treating animals. All animal studies were carried out in accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and associated guidelines.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2017

BMC Cancer 1/2017 Zur Ausgabe

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise